Globulin-platelet model predicts minimal fibrosis and cirrhosis in chronic hepatitis B virus infected patients

Abstract

By establishing a simple model using available laboratory variables, chronic HBV-infected patients with minimal fibrosis and cirrhosis can be diagnosed accurately, and the clinical application of this model may reduce the need for liver biopsy in HBV-infected patients.

The diagnostic value of a globulin/platelet model for evaluating liver fibrosis in chronic hepatitis B patients

“…To date, there has been only one study that has evaluated the GP model to predict significant fibrosis in CHB patients. Liu et al (13) derived and validated the GP model in a cohort of 114 patients with CHB. They reported that the AUROC of the GP model for the predicting significant fibro- In earlier studies, serum globulin, immunoglobulin levels and platelets demonstrated high predictive value for the extent of hepatic fibrosis in patients with CHB and CHC (13,19).…”

“…Liu et al (13) derived and validated the GP model in a cohort of 114 patients with CHB. They reported that the AUROC of the GP model for the predicting significant fibro- In earlier studies, serum globulin, immunoglobulin levels and platelets demonstrated high predictive value for the extent of hepatic fibrosis in patients with CHB and CHC (13,19). Schmilovitz-Weiss et al (20) reported that serum globulin levels were the strongest predictors of severe fibrosis (OR 5.97, 95% CI 1.82-19.53, p = 0.0004), followed by platelet count (OR 0.98, 95% CI 0.97-0.99, p: 0.001) and serum Ig G level (OR 1.003, 95% CI 1.000-1.007, p < 0.042).…”

“…These markers include AAR (aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio), APRI (AST/platelet ratio index), API (age-platelet index), APGA [AST/Platelet/Gammaglutamyl transpeptidase (GGT)/Alfa-fetoprotein (AFP)] (8), CDS (cirrhosis discriminate score) (9), FI (Fibrosis index) (10), Göteborg University cirrhosis index (GUCI) (11) and Fibro-quotient (Fibro Q) (12). The GP model (including globulin and platelets) is a newly developed model for predicting significant liver fibrosis in patients with CHB (13). To date, only one study has evaluated the GP model in association with significant fibrosis in patients with CHB.…”

SHFI: A Novel Noninvasive Predictive Model for Significant Fibrosis in Patients With Chronic Hepatitis B

“…In studies performed on patients with CHB, AUC values of Fib-4 were 0.768, 0.687, 0.701, 0.720, and 0.750 for 0.73 (35), 1.09 (36), 1.02 (37), 1.7 (38), and 1.45 (39) cut off values, respectively. It was shown that AUC was 0.885 for cut off value of 1.09 and more effective for predicting significant fibrosis in patients with CHB.…”

Treat-to-Target in Autoimmune Hepatitis: How Far To Go?

“…Similar to other chronic liver diseases, of which several noninvasive models based on demographic and biochemical parameters have been developed to evaluate the severity of inflammation and fibrosis [51][52][53][54]. More reliable evaluating systems of disease activities need to be further explored in AIH.…”